These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6594322)

  • 1. Enoxacin: worldwide in-vitro activity against 22451 clinical isolates.
    Siporin C; Towse G
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():47-55. PubMed ID: 6594322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
    Duncan IB; Skulnick M; Marshall PW
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():1-6. PubMed ID: 6438046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antibacterial activity of enoxacin (CI-919).
    Fernandes CJ; Munro R; Toohey M; Shanker S; Mallon R; Daley D; Harland GS; Stevens DA; Wilson RD; Ackerman VP
    Pathology; 1986 Apr; 18(2):240-2. PubMed ID: 3093961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
    Wise R; Andrews JM; Danks G
    J Antimicrob Chemother; 1984 Mar; 13(3):237-44. PubMed ID: 6586712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
    Floyd-Reising SA; Kelley SG; Hindler JA; Young LS
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):301-6. PubMed ID: 3472704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity.
    Reeves DS; Bywater MJ; Holt HA
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():7-17. PubMed ID: 6594324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
    King A; Shannon K; Slegg J; Phillips I
    J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of enoxacin compared with norfloxacin and amikacin.
    van der Auwera P; de Moor G; Lacroix G; Mambour A; Rossion N; Schuyteneer F
    Eur J Clin Microbiol; 1985 Feb; 4(1):55-8. PubMed ID: 3157568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
    Ling TK; Liu EY; Cheng AF
    Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of E-4695, a new fluoro-naphthyridine.
    Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):188-94. PubMed ID: 1327787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM; Zemcov SJ; Campbell ME
    J Antimicrob Chemother; 1985 Jan; 15(1):39-44. PubMed ID: 3156112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of a new penem FCE 22101.
    Hoban DJ
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():53-7. PubMed ID: 2786518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
    Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
    Gooding BB; Jones RN
    Antimicrob Agents Chemother; 1993 Feb; 37(2):349-53. PubMed ID: 8043036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agents.
    Jones RN; Ayers LW; Barry AL; Gerlach EH; Sommers HM; Thornsberry C; Fuchs PC
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):315-26. PubMed ID: 3698544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.